Skip to main content

A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).

Publication ,  Conference
Attia, S; Sankhala, KK; Riedel, RF; Robinson, SI; Conry, RM; Boland, PM; Barve, MA; Fritchie, K; Seon, BK; Alvarez, D; Adams, BJ; Shazer, RL ...
Published in: Journal of Clinical Oncology
May 20, 2016

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2016

Volume

34

Issue

15_suppl

Start / End Page

11016 / 11016

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Attia, S., Sankhala, K. K., Riedel, R. F., Robinson, S. I., Conry, R. M., Boland, P. M., … Maki, R. G. (2016). A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS). In Journal of Clinical Oncology (Vol. 34, pp. 11016–11016). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.11016
Attia, Steven, Kamalesh Kumar Sankhala, Richard F. Riedel, Steven Ian Robinson, Robert Martin Conry, Patrick McKay Boland, Minal A. Barve, et al. “A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).” In Journal of Clinical Oncology, 34:11016–11016. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.11016.
Attia S, Sankhala KK, Riedel RF, Robinson SI, Conry RM, Boland PM, et al. A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 11016–11016.
Attia, Steven, et al. “A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 11016–11016. Crossref, doi:10.1200/jco.2016.34.15_suppl.11016.
Attia S, Sankhala KK, Riedel RF, Robinson SI, Conry RM, Boland PM, Barve MA, Fritchie K, Seon BK, Alvarez D, Adams BJ, Shazer RL, Theuer CP, Maki RG. A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 11016–11016.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2016

Volume

34

Issue

15_suppl

Start / End Page

11016 / 11016

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences